NCT04669262View on ClinicalTrials.gov

BGB-DXP604 Alone and in Combination With BGB-DXP593 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 9, 2020

Primary Completion Date

May 21, 2021

Study Completion Date

May 21, 2021

Conditions
Healthy
Interventions
DRUG

BGB-DXP604

Administered as intravenous (IV) infusion over 30 to 60 minutes

DRUG

BGB-DXP593

Administered as intravenous (IV) infusion over 30 to 60 minutes

DRUG

Placebo

Placebo to match BGB-DXP593

DRUG

Placebo

Placebo to match BGB-DXP604

Trial Locations (1)

4006

Q PHARM, Herston

Sponsors

Lead Sponsor

BeiGene
All Listed Sponsors
lead

BeiGene

INDUSTRY

NCT04669262 - BGB-DXP604 Alone and in Combination With BGB-DXP593 in Healthy Participants | Biotech Hunter | Biotech Hunter